FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570597673> ?p ?o ?g. }

• W2570597673 endingPage "779" @default.
• W2570597673 startingPage "771" @default.
• W2570597673 abstract "Background Controversy exists about any differences in longer-term safety across different intravenous iron formulations routinely used in hemodialysis (HD) patients. We exploited a natural experiment to compare outcomes of patients initiating HD therapy in facilities that predominantly (in ≥90% of their patients) used iron sucrose versus sodium ferric gluconate complex. Study Design Retrospective cohort study of incident HD patients. Setting & Participants Using the US Renal Data System, we hard-matched on geographic region and center characteristics HD facilities predominantly using ferric gluconate with similar ones using iron sucrose. Subsequently, incident HD patients were assigned to their facility iron formulation exposure. Intervention Facility-level use of iron sucrose versus ferric gluconate. Outcomes Patients were followed up for mortality from any, cardiovascular, or infectious causes. Medicare-insured patients were followed up for infectious and cardiovascular (stroke or myocardial infarction) hospitalizations and for composite outcomes with the corresponding cause-specific deaths. Measurements HRs. Results We matched 2,015 iron sucrose facilities with 2,015 ferric gluconate facilities, in which 51,603 patients (iron sucrose, 24,911; ferric gluconate, 26,692) subsequently initiated HD therapy. All recorded patient characteristics were balanced between groups. Over 49,989 person-years, 10,381 deaths (3,908 cardiovascular and 1,209 infectious) occurred. Adjusted all-cause (HR, 0.98; 95% CI, 0.93-1.03), cardiovascular (HR, 0.96; 95% CI, 0.89-1.03), and infectious mortality (HR, 0.98; 95% CI, 0.86-1.13) did not differ between iron sucrose and ferric gluconate facilities. Among Medicare beneficiaries, no differences between ferric gluconate and iron sucrose facilities were observed in fatal or nonfatal cardiovascular events (HR, 1.01; 95% CI, 0.93-1.09). The composite infectious end point occurred less frequently in iron sucrose versus ferric gluconate facilities (HR, 0.92; 95% CI, 0.88-0.96). Limitations Unobserved selection bias from nonrandom treatment assignment. Conclusions Patients initiating HD therapy in facilities almost exclusively using iron sucrose versus ferric gluconate had similar longer-term outcomes. However, there was a small decrease in infectious hospitalizations and deaths in patients dialyzing in facilities predominantly using iron sucrose. This difference may be due to residual confounding, random chance, or a causal effect. Controversy exists about any differences in longer-term safety across different intravenous iron formulations routinely used in hemodialysis (HD) patients. We exploited a natural experiment to compare outcomes of patients initiating HD therapy in facilities that predominantly (in ≥90% of their patients) used iron sucrose versus sodium ferric gluconate complex. Retrospective cohort study of incident HD patients. Using the US Renal Data System, we hard-matched on geographic region and center characteristics HD facilities predominantly using ferric gluconate with similar ones using iron sucrose. Subsequently, incident HD patients were assigned to their facility iron formulation exposure. Facility-level use of iron sucrose versus ferric gluconate. Patients were followed up for mortality from any, cardiovascular, or infectious causes. Medicare-insured patients were followed up for infectious and cardiovascular (stroke or myocardial infarction) hospitalizations and for composite outcomes with the corresponding cause-specific deaths. HRs. We matched 2,015 iron sucrose facilities with 2,015 ferric gluconate facilities, in which 51,603 patients (iron sucrose, 24,911; ferric gluconate, 26,692) subsequently initiated HD therapy. All recorded patient characteristics were balanced between groups. Over 49,989 person-years, 10,381 deaths (3,908 cardiovascular and 1,209 infectious) occurred. Adjusted all-cause (HR, 0.98; 95% CI, 0.93-1.03), cardiovascular (HR, 0.96; 95% CI, 0.89-1.03), and infectious mortality (HR, 0.98; 95% CI, 0.86-1.13) did not differ between iron sucrose and ferric gluconate facilities. Among Medicare beneficiaries, no differences between ferric gluconate and iron sucrose facilities were observed in fatal or nonfatal cardiovascular events (HR, 1.01; 95% CI, 0.93-1.09). The composite infectious end point occurred less frequently in iron sucrose versus ferric gluconate facilities (HR, 0.92; 95% CI, 0.88-0.96). Unobserved selection bias from nonrandom treatment assignment. Patients initiating HD therapy in facilities almost exclusively using iron sucrose versus ferric gluconate had similar longer-term outcomes. However, there was a small decrease in infectious hospitalizations and deaths in patients dialyzing in facilities predominantly using iron sucrose. This difference may be due to residual confounding, random chance, or a causal effect." @default.
• W2570597673 created "2017-01-13" @default.
• W2570597673 creator A5014965271 @default.
• W2570597673 creator A5016502106 @default.
• W2570597673 creator A5018138746 @default.
• W2570597673 creator A5020277057 @default.
• W2570597673 creator A5020579382 @default.
• W2570597673 creator A5042134184 @default.
• W2570597673 creator A5049275831 @default.
• W2570597673 creator A5067727757 @default.
• W2570597673 creator A5091721413 @default.
• W2570597673 date "2017-06-01" @default.
• W2570597673 modified "2023-09-30" @default.
• W2570597673 title "Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex" @default.
• W2570597673 cites W1858532931 @default.
• W2570597673 cites W1863012309 @default.
• W2570597673 cites W1973420370 @default.
• W2570597673 cites W2045243132 @default.
• W2570597673 cites W2054214398 @default.
• W2570597673 cites W2076859422 @default.
• W2570597673 cites W2085784457 @default.
• W2570597673 cites W2108667710 @default.
• W2570597673 cites W2110622197 @default.
• W2570597673 cites W2126049444 @default.
• W2570597673 cites W2154976325 @default.
• W2570597673 cites W2158623958 @default.
• W2570597673 cites W2163535392 @default.
• W2570597673 cites W2179358297 @default.
• W2570597673 cites W2222807855 @default.
• W2570597673 cites W2227451369 @default.
• W2570597673 cites W2331533320 @default.
• W2570597673 cites W2338266315 @default.
• W2570597673 cites W2580449060 @default.
• W2570597673 doi "https://doi.org/10.1053/j.ajkd.2016.10.031" @default.
• W2570597673 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5441933" @default.
• W2570597673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28063734" @default.
• W2570597673 hasPublicationYear "2017" @default.
• W2570597673 type Work @default.
• W2570597673 sameAs 2570597673 @default.
• W2570597673 citedByCount "8" @default.
• W2570597673 countsByYear W25705976732017 @default.
• W2570597673 countsByYear W25705976732020 @default.
• W2570597673 crossrefType "journal-article" @default.
• W2570597673 hasAuthorship W2570597673A5014965271 @default.
• W2570597673 hasAuthorship W2570597673A5016502106 @default.
• W2570597673 hasAuthorship W2570597673A5018138746 @default.
• W2570597673 hasAuthorship W2570597673A5020277057 @default.
• W2570597673 hasAuthorship W2570597673A5020579382 @default.
• W2570597673 hasAuthorship W2570597673A5042134184 @default.
• W2570597673 hasAuthorship W2570597673A5049275831 @default.
• W2570597673 hasAuthorship W2570597673A5067727757 @default.
• W2570597673 hasAuthorship W2570597673A5091721413 @default.
• W2570597673 hasBestOaLocation W25705976732 @default.
• W2570597673 hasConcept C126322002 @default.
• W2570597673 hasConcept C141071460 @default.
• W2570597673 hasConcept C167135981 @default.
• W2570597673 hasConcept C191897082 @default.
• W2570597673 hasConcept C192562407 @default.
• W2570597673 hasConcept C2776974161 @default.
• W2570597673 hasConcept C2777417653 @default.
• W2570597673 hasConcept C2778063415 @default.
• W2570597673 hasConcept C2778248108 @default.
• W2570597673 hasConcept C2780534640 @default.
• W2570597673 hasConcept C3020614022 @default.
• W2570597673 hasConcept C500558357 @default.
• W2570597673 hasConcept C71924100 @default.
• W2570597673 hasConcept C90924648 @default.
• W2570597673 hasConceptScore W2570597673C126322002 @default.
• W2570597673 hasConceptScore W2570597673C141071460 @default.
• W2570597673 hasConceptScore W2570597673C167135981 @default.
• W2570597673 hasConceptScore W2570597673C191897082 @default.
• W2570597673 hasConceptScore W2570597673C192562407 @default.
• W2570597673 hasConceptScore W2570597673C2776974161 @default.
• W2570597673 hasConceptScore W2570597673C2777417653 @default.
• W2570597673 hasConceptScore W2570597673C2778063415 @default.
• W2570597673 hasConceptScore W2570597673C2778248108 @default.
• W2570597673 hasConceptScore W2570597673C2780534640 @default.
• W2570597673 hasConceptScore W2570597673C3020614022 @default.
• W2570597673 hasConceptScore W2570597673C500558357 @default.
• W2570597673 hasConceptScore W2570597673C71924100 @default.
• W2570597673 hasConceptScore W2570597673C90924648 @default.
• W2570597673 hasFunder F4320337357 @default.
• W2570597673 hasIssue "6" @default.
• W2570597673 hasLocation W25705976731 @default.
• W2570597673 hasLocation W25705976732 @default.
• W2570597673 hasLocation W25705976733 @default.
• W2570597673 hasLocation W25705976734 @default.
• W2570597673 hasOpenAccess W2570597673 @default.
• W2570597673 hasPrimaryLocation W25705976731 @default.
• W2570597673 hasRelatedWork W113810927 @default.
• W2570597673 hasRelatedWork W1863012309 @default.
• W2570597673 hasRelatedWork W2089210834 @default.
• W2570597673 hasRelatedWork W2349577045 @default.
• W2570597673 hasRelatedWork W2359342557 @default.
• W2570597673 hasRelatedWork W2363740212 @default.
• W2570597673 hasRelatedWork W2372269450 @default.
• W2570597673 hasRelatedWork W2376065150 @default.
• W2570597673 hasRelatedWork W3174717294 @default.

• next